# INFARMED, National Authority of Medicines and Health Products (Portugal)

Source: https://onco.cc/institutions/infarmed/  
OnCo record `infarmed` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Portugal's medicines regulator, which also runs the national health technology assessment system, SiNATS. A cancer medicine authorised for the whole EU still needs a SiNATS assessment before NHS hospitals may buy it or the state may reimburse it.

## Summary

INFARMED, the Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., is the public institute that regulates medicines, medical devices and clinical trials in Portugal. New cancer medicines are authorised once for the whole European Union through the European Medicines Agency's centralised procedure.

Decree-Law 97/2015 of 1 June 2015 created the Sistema Nacional de Avaliação de Tecnologias de Saúde (SiNATS), managed by INFARMED, covering every public and private body that produces, sells or uses health technologies, with technical, therapeutic and economic assessment. Its preamble states that placing a technology on the market is a necessary but not sufficient condition for NHS funding, and it introduced contracts with the marketing authorisation holder as the instrument for reimbursement (comparticipação) and for the prior assessment (avaliação prévia) that every prescription medicine NHS bodies are to buy must pass, which weighs therapeutic innovation against economic advantage and sets a maximum purchase price. Law 53/2017 links the national cancer registry to INFARMED for monitoring the effectiveness of medicines in use. The OECD and European Commission's 2025 profile reports a mean of 748 days from EMA approval to a coverage decision for a sample of breast and lung cancer medicines, 45% longer than the EU average, and 266 days for cancer biosimilars against an EU average of 505; it also cites INFARMED's figures of 203 clinical trials approved in 2023, against 99 in 2012, 58 of them for antineoplastic and immunomodulatory drugs.

## Fields

- Kind: Institution
- Last checked: 2026-11-11
- Also known as: INFARMED; INFARMED, I.P.; Autoridade Nacional do Medicamento e Produtos de Saúde
- City: Lisbon, PT
- Type: government
- Website: https://www.infarmed.pt

## Sources

- Decreto-Lei n.º 97/2015, de 1 de junho: cria o SiNATS (Diário da República PDF): https://data.dre.pt/eli/dec-lei/97/2015/06/01/p/dre/pt/pdf
- INFARMED: https://www.infarmed.pt
- OECD/EC, Country Cancer Profile Portugal 2025, sections 5.1 and 5.2 (PDF, Internet Archive copy): https://web.archive.org/web/20261013171208/https://cancer-inequalities.jrc.ec.europa.eu/sites/default/files/docs/ccp2025/ec-oecd-pt-2024-1681-en.pdf

## Connected records

- institutions: [European Medicines Agency](https://onco.cc/institutions/ema/), [Portuguese National Cancer Registry (Registo Oncológico Nacional)](https://onco.cc/institutions/ron-portugal/), [Portuguese National Health Service (Serviço Nacional de Saúde)](https://onco.cc/institutions/sns-portugal/)

---
JSON: https://onco.cc/api/v1/entities/infarmed.json